Venetoclax and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome: Bursa Uludag University Experience

İbrahim Ethem PINAR; Fahir ÖZKALEMKAŞ; Vildan OZKOCAMAN; Tuba ERSAL; Cumali YALÇIN; Bedrettin ORHAN; Ömer CANDAR

doi:https://doi.org/10.46310/tjim.877068

Article Details

Venetoclax and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome: Bursa Uludag University Experience

Authors:

İbrahim Ethem PINAR | Fahir ÖZKALEMKAŞ | Vildan OZKOCAMAN | Tuba ERSAL | Cumali YALÇIN | Bedrettin ORHAN | Ömer CANDAR

Publisher:

Nizameddin KOCA

Main Topics:

Diseases

Journal:

Turkish Journal of Internal Medicine 2021 Vol.3 Issue Supplement 1, pp.42-43

Document Type:

Article

Publication Date:

3/2021

Document Language:

English

Document ID (Org No.):

2000637759

Frequency:

Quarterly

eISSN:

2687-4245

DOI:

https://doi.org/10.46310/tjim.877068

Abstract:

 

The management of acute myeloid leukemia (AML) gradually turns into an individualized approach with the application of targeted therapies. Venetoclax is a BCL-2 inhibitor that is synergistic with azacitidine. In this case series, 14 patients diagnosed with relapsed / refractory AML and 1 MDS RAEB-1 were followed up with venetoclax + azacitidine in the Hematology Department Bursa Uludag University Faculty of Medicine were evaluated. The best responses obtained with venetoclax + azacitidine were complete remission (CR) in one patient, complete remission with incomplete hematologic recovery (CRi) in one patient, morphological leukemia-free state (MLFS) in 4 patients, and partial response (PR) in one patient. The median time to first response with treatment was one month (0.5-5). The time to enter early remission is critical. For this reason, deaths due to infection should be prevented. Although the toxicities of this combination therapy can be managed, close follow-up of the patients is mandatory. In conclusion, this combination therapy is promising as it is relatively well-tolerated, improves the quality of life, and prolongs survival.

Article Details

Venetoclax and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome: Bursa Uludag University Experience

Authors: İbrahim Ethem PINAR | Fahir ÖZKALEMKAŞ | Vildan OZKOCAMAN | Tuba ERSAL | Cumali YALÇIN | Bedrettin ORHAN | Ömer CANDAR

Publisher: Nizameddin KOCA

Main Topics: Diseases

Journal: Turkish Journal of Internal Medicine 2021 Vol.3 Issue Supplement 1, pp.42-43

Document Type: Article

Publication Date: 3/2021

Document Language: English

Document ID (Org No.): 2000637759

Frequency: Quarterly

eISSN: 2687-4245

DOI: https://doi.org/10.46310/tjim.877068

Issues

Authors:

İbrahim Ethem PINAR | Fahir ÖZKALEMKAŞ | Vildan OZKOCAMAN | Tuba ERSAL | Cumali YALÇIN | Bedrettin ORHAN | Ömer CANDAR

Publisher:

Nizameddin KOCA

Main Topics:

Diseases

Journal:

Turkish Journal of Internal Medicine 2021 Vol.3 Issue Supplement 1, pp.42-43

Document Type:

Article

Publication Date:

3/2021

Document Language:

English

Document ID (Org No.):

2000637759

Frequency:

Quarterly

eISSN:

2687-4245

DOI:

https://doi.org/10.46310/tjim.877068